ASTM E2882-19 - 1.8.2019
 
Significance and Use

4.1 An analyst should be knowledgeable, through established laboratory training, of clandestine drug laboratory synthetic routes and the techniques used in the analysis of related samples. This acquired knowledge of clandestine drug laboratory samples assists the analyst in choosing the best analytical scheme to identify reagents, precursors, intermediates, and final products.

4.2 The qualitative and quantitative analyses of clandestine drug laboratory evidence can require different approaches relative to routine seized drug analyses. Analysts shall understand the limitations of the procedures used in their qualitative and quantitative analyses. These include such factors as method selectivity, uncertainty, and the basis for inferences from a sample(s) to a population.

4.3 Laboratory management shall ensure that clandestine drug laboratory synthesis and analysis training be provided through relevant procedures, literature, and practical experience. Practical experience typically includes production, sampling and analysis of clandestine drug laboratory training samples.

4.4 Laboratory management shall ensure that chemical safety and hygiene plans address and mitigate hazards associated with clandestine drug laboratory evidence.

4.5 It does not address scene attendance or scene processing.

4.6 Laboratory management shall consider customer/local requirements which influence the application of these recommendations.

 
1. Scope

1.1 This standard is intended to be used in conjunction with the general requirements for the analysis of seized drugs (Practices E2326, E2327, E2329, and E2549; Guides E2548 and E2329). This standard provides guidance on the chemical analysis of items and samples related to suspected clandestine drug laboratories. This standard provides general guidance for the analysis of clandestine drug laboratory evidence and is not a substitute for detailed and validated laboratory policies and technical procedures.

1.2 This standard cannot replace knowledge, skills, or abilities acquired through education, training, and experience (see Practice E2326) and is to be used in conjunction with professional judgment by individuals with such discipline-specific knowledge, skills, and abilities.

1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.4 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

 
2. Referenced Documents

E2548-26

Standard Practice for Sampling Seized Drugs for Qualitative and Quantitative Analysis

E2549-14

Standard Practice for Validation of Seized-Drug Analytical Methods (Withdrawn 2023)

F2725-19(2025)

Standard Guide for European Union“s Registration, Evaluation, and Authorization of Chemicals (REACH) Supply Chain Information Exchange

E2329-25

Standard Practice for Designing Analytical Schemes for the Identification of Chemical Substances in Suspected Seized Drug Evidence

E2363-23

Standard Terminology Relating to Manufacturing of Pharmaceutical and Biopharmaceutical Products in the Pharmaceutical and Biopharmaceutical Industry

D6161-19

Standard Terminology Used for Microfiltration, Ultrafiltration, Nanofiltration, and Reverse Osmosis Membrane Processes

E1605-26a

Standard Terminology Relating to Lead in Buildings (Includes all amendments and changes 4/9/2026).

E2326-14

Standard Practice for Education and Training of Seized-Drug Analysts (Withdrawn 2023)

E2327-15

Standard Practice for Quality Assurance of Laboratories Performing Seized-Drug Analysis